Heparinized Vascular Catheters: A Clinical Trial

Eldh, Per; Jacobsson, Bo

doi:10.1148/111.2.289

Cited by 26 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that, within similar time frames, heparin-coated catheters accumulate fewer thrombi and, thus, should reduce cerebral embolic complications . However, although heparin coating reduces thrombus formation , it does not eliminate it as an earlier report suggests [17].…”

Section: Discussionmentioning

confidence: 83%

Thrombogenicity of heparin- and non-heparin-coated catheters: clinical trail

Dk¹,

Paulin²,

Alenghat³

et al. 1982

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

Thrombogenicity of heparin- and non-heparin-coated catheters: clinical trail

Dk¹,

Paulin²,

Alenghat³

et al. 1982

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

“…The accumulation of platelets on the catheters was less than 10 per cent of that on untreated catheters. Recently, ELDH & JACOBSSON (1974)have shown that the use of catheters with heparin-coated surface has dramatically reduced the incidence of thromboembolic complications. BOURASSA et coIl.…”

Section: Discussionmentioning

confidence: 99%

Thromboembolic Complications in Coronary Angiography

Storstein¹,

Nitter-Hauge²,

Enge³

1977

Acta Radiologica. Diagnosis

View full text Add to dashboard Cite

show abstract

“…The use of plastic catheters for cardiac diagnostics is universal. It has been demonstrated by pull-out angiograms that the large doses of heparin used intravenously with this technic are not effective in preventing the formation of a ring of thrombus on the end of the catheter [23]. The thrombus dislodged as the catheter is removed may have been responsible for fatal thromboembolism with this procedure [32].…”

Section: Heparin Coatingsmentioning

confidence: 99%

Pharmacodynamics and Clinical Effectiveness of Heparin

Jaques¹,

Mahadoo²

2008

Semin Thromb Hemost

View full text Add to dashboard Cite

It has been generally assumed that the clinical use of heparin is simply an extension of the initial laboratory use to prevent blood coagulation in test tubes and cannulae. Here the effects of mixing heparin with blood appear to be the same in vivo and in vitro. Evidence was obtained early that this was an oversimplification of the situation and the large amount of data that has now accumulated calls for a reevaluation of this basic assumption in a number of aspects which bear on the clinical use of this important drug. DISSIMILARITY BETWEEN IN VIVO and IN VITRO EFFECTS OF HEPARINThe most clear-cut demonstration that the effects of heparin in vivo are not the same as those when this drag is added to blood in vitro is the appearance of enzymes in the general circulation which were not present in significant amounts before injection of the drug-e.g., lipoprotein lipase [70] and diamine oxidase [15], also known as histaminase. This dissimilarity was early indicated for the effect of heparin on thrombosis when compared with coagulation tests in vitro. Solandt and Best [103], in the initial paper to report the use of heparin in an extracorporeal circulation, measured the effectiveness of heparin in preventing platelet thrombi in glass chambers inserted in arteriovenous shunts in dogs. Immediately after the injection of heparin, the clotting time reached infinity (the blood became incoagulable), as was the case when a comparable amount of heparin was added to the blood outside the body. However, formation of thrombi was not prevented until 20-60 minutes after the injection. When the clotting time had again become measurable 2-7 hours later, thrombus formation did not occur. It was not for yet another hour (when the clotting time was essentially normal) that accumulation of platelets and formation of thrombi occurred again in the shunt. Hence, the anticoagulant effect and the prevention of thrombus formation appeared to be two distinct properties of heparin.

show abstract

Heparinized Vascular Catheters: A Clinical Trial

Cited by 26 publications

References 0 publications

Thrombogenicity of heparin- and non-heparin-coated catheters: clinical trail

Thrombogenicity of heparin- and non-heparin-coated catheters: clinical trail

Thromboembolic Complications in Coronary Angiography

Pharmacodynamics and Clinical Effectiveness of Heparin

Contact Info

Product

Resources

About